

72.(New) The composition of Claim 63, wherein the endostatin protein and the angiostatin protein inhibit angiogenesis *in vitro*.

73.(New) The composition of Claim 63, wherein the endostatin protein has an N-terminal amino acid sequence as shown in SEQ ID NO:1.

REMARKS

The present application is directed to endostatin proteins, which are useful for the inhibition of angiogenesis and the treatment of angiogenesis-dependent diseases such as cancer. As used in the present specification, the term "isolated" refers to material which is free from at least some of the constituents within which it is naturally associated.

Claims 34-51 have been cancelled and claims 52-73 have been added, however, no new matter is contained therein. No additional fees are believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-1215. In light of the amendments and the above remarks, Applicants are of the opinion that the application is now in condition for allowance. Such action is respectfully requested.

If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 949-2400 is respectfully solicited.

Respectfully submitted,

JONES & ASKEW, L.L.P.



By: Lisa C. Elsevier
Reg. No. 44,669

JONES & ASKEW, L.L.P.
2400 Monarch Tower
3424 Peachtree Road, N.E.
Atlanta, Georgia 30326
Attorney Docket No. 05213-0640